Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential multi-target CAR-T therapy for pediatric relapsed/refractory B-cell lymphoma
ChiCTR2000030954Phase 2Not yet recruiting
- Sponsor
- Beijing Boren Hospital
- Start
- Mar 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19 CAR-T cells, CD20 CAR-T cells and CART22-65s in mature B-cell lymphoma and malignant B-cell neoplasm, sponsored by Beijing Boren Hospital. Primary endpoint: Safety index. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
CD19 CAR-T cellsCD20 CAR-T cellsCART22-65s
03
Conditions
mature B-cell lymphomamalignant B-cell neoplasm
Beyond the preview
Go deeper on ChiCTR2000030954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030954.